drugset / Trial / NCT07797335

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

NCT07797335 ↗

Phase 3 Recruiting 1778 enrolled Novo Nordisk A/S
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medications. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide, (the treatment being tested) or insulin glargine (a comparator) and which treatment participants get is decided by chance.

Timeline

Start
2026-08-24
Primary completion
2028-07-31
Completion
2028-09-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Zenagamtide Unknown — Subcutaneous
Comparator insulin glargine Protein / enzyme biologic — Subcutaneous